A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children by Mostafa, Gehan Ahmed & AL-Ayadhi, Laila Yousef
RESEARCH Open Access
A lack of association between hyperserotonemia
and the increased frequency of serum anti-myelin
basic protein auto-antibodies in autistic children
Gehan Ahmed Mostafa
1,2* and Laila Yousef AL-Ayadhi
1
Abstract
Background: One of the most consistent biological findings in autism is the elevated blood serotonin levels.
Immune abnormalities, including autoimmunity with production of brain specific auto-antibodies, are also
commonly observed in this disorder. Hyperserotonemia may be one of the contributing factors to autoimmunity in
some patients with autism through the reduction of T-helper (Th) 1-type cytokines. We are the first to investigate
the possible role of hyperserotonemia in the induction of autoimmunity, as indicated by serum anti-myelin-basic
protein (anti-MBP) auto-antibodies, in autism.
Methods: Serum levels of serotonin and anti-MBP auto-antibodies were measured, by ELISA, in 50 autistic patients,
aged between 5 and 12 years, and 30 healthy-matched children.
Results: Autistic children had significantly higher serum levels of serotonin and anti-MBP auto-antibodies than
healthy children (P < 0.001 and P < 0.001, respectively). Increased serum levels of serotonin and anti-MBP auto-
antibodies were found in 92% and 80%, respectively of autistic patients. Patients with severe autism had
significantly higher serum serotonin levels than children with mild to moderate autism (P < 0.001). Serum
serotonin levels had no significant correlations with serum levels of anti-MBP auto-antibodies in autistic patients
(P = 0.39).
Conclusions: Hyperserotonemia may not be one of the contributing factors to the increased frequency of serum
anti-MBP auto-antibodies in some autistic children. These data should be treated with caution until further
investigations are performed. However, inclusion of serum serotonin levels as a correlate may be useful in other
future immune studies in autism to help unravel the long-standing mystery of hyperserotonemia and its possible
role in the pathophysiology of this disorder.
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1. Introduction
Autoimmunity to CNS may have a pathogenic role in
autism [1]. This may be indicated by the presence of
brain-specific auto-antibodies in some autistic children
[2-8]. There is also an increase in the frequency of auto-
immune disorders among autistic families [9-15].
Serotonin is formed by hydroxylation and decarboxy-
lation of tryptophan. Serotonin is known to play a role
in brain development prior to the time it assumes its
role as a neurotransmitter. Disruption of serotonergic
development can leave permanent alterations in brain
function and behavior. This may be the case in autism
[16,17]. It was suggested that autism, without a discern-
ible cause, may be a genetic disorder of serotonin meta-
bolism. The interest in assessing serotonergic function
in autism stems from its role in perception and filtering
of sensory signals, social attachment and facilitation of
formation of synapses which is crucial to acquire learn-
ing and memory [18]. Blood serotonin might serve as
analogue marker for serotonergic function [19].
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sion, has been shown to modulate immune responses.
Serotonin may contribute to asthma pathogenesis
through reduction of Th1-type cytokines [20]. In addi-
tion, hyperserotonemia may promote autoimmunity
through reduction of Th1-type cytokines. This may
result in an imbalance of T-helper (Th)1/Th2 subsets
toward Th2, which are responsible for the allergic
response and the production of antibodies. Hypersero-
tonemia may also promote autoimmunity through
initiation of the delayed-type hypersensitivity
responses, which has been proposed as a pathological
mechanism leading to autism [21]. Accordingly,
modifiers of the serotonin transmitter system such as
compounds that affect the serotonin transporter,
prejunctional serotonin receptors or postsynaptic sero-
tonin receptors might represent a novel treatment of
asthma and autoimmune disorders [22].
With this background, this study was conducted to
investigate the relationship between serum levels of
serotonin and anti-myelin-basic protein (anti-MBP)
auto-antibodies, which are possible indicators of autoim-
munity to CNS, in a group of autistic children.
2. Methods
Study population
This case-control study was conduced on 50 children
who had classic-onset autism. The patients were fulfill-
ing the criteria for the diagnosis of autism according to
the 4th edition of the Diagnostic and Statistical Manual
of Mental Disorders [23].
The autistic group comprised 41 males and 9 females.
They were recruited from the Autism Research and
Treatment Center, Faculty of Medicine, King Saud Uni-
versity, Riyadh, Saudi Arabia. Their ages ranged between
5 and 12 years (mean ± SD = 8.22 ± 2.28 years).
Inclusion criteria
1-Patients who had no associated neurological diseases
(such as cerebral palsy, tuberous sclerosis).
2-Patients who had no associated metabolic disorders
(eg. Phenylketonuria) because these associated comor-
bidities with autism may influence the results of serum
serotonin and anti-MBP levels.
3-Patients who were not receiving any medications.
The control group comprised 30 age-and sex-matched
apparently healthy children. They included 25 males and
5 females. They were the healthy older siblings of the
healthy children who attend the Well Baby Clinic, King
Khalid University Hospital, Faculty of Medicine, King
Saud University, Riyadh, Saudi Arabia for routine follow
up of their growth parameters. The control children
were not related to the children with autism, and
demonstrated no clinical findings suggestive of immuno-
logical or neuropsychiatric disorders. Their ages ranged
between 5 and 12 years (mean ± SD = 8.23 ± 2.36
years).
The local Ethical Committee of the Faculty of Medi-
cine, King Saud University, Riyadh, Saudi Arabia,
approved this study. In addition, an informed written
consent of participation in the study was signed by the
parents or the legal guardians of the studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on the clinical history taking from the
caregivers, clinical examination and neuropsychiatric
assessment. In addition, the degree of the severity of
autism was assessed by using the Childhood Autism
Rating Scale (CARS) [24] which rates the child on a
scale from one to four in each of fifteen areas (relating
to people; emotional response; imitation; body use;
object use; listening response; fear or nervousness;
verbal communication; non-verbal communication;
activity level; level and consistency of intellectual
response; adaptation to change; visual response; taste,
smell and touch response and general impressions).
According to the scale, children who have scored
30-36 have mild to moderate autism (n = 17), while
those with scores ranging between 37 and 60 points
have severe autism (n = 33).
Assessment of serum serotonin levels
Serum serotonin levels were assayed by using serotonin
EIA kit (Biosource Europe S.A. rue de l’industrie 8 1400
Nivelles Belgium). Principally, the competitive serotonin
EIA kit uses the microtiter plate format. Serotonin is
bound to the solid phase of the microtiter plate.
Acylated serotonin and solid phase bound serotonin
compete for a fixed number of antiserum binding sites.
When the system is in equilibrium, free antigen and free
antigen-antiserum complexes are removed by washing.
The antibody bound to the solid phase serotonin is
detected by anti-rabbit peroxidase. The substrate TMB/
peroxidase reaction is read at 450 nm with a filter wave
length 620 nm. The corresponding serotonin con-
centrations are determined from the standard curve by
matching their mean absorbance readings with the
corresponding serotonin concentrations in ng/ml. To
increase accuracy, all samples were analyzed twice in
two independent experiments to assess inter-assay varia-
tions and to ensure reproducibility of the observed
results (P > 0.05).
Measurement of serum anti-myelin basic protein (anti-MBP)
antibodies
This was done by using ELISA kit that allows for the
specific measurement of human anti-MBP (Diagnostic
Systems, Texas, USA). This assay recognizes recombi-
nant and natural human MBP antibodies. Principally,
the microtiter plate provided in this kit has been pre-
Mostafa and AL-Ayadhi Journal of Neuroinflammation 2011, 8:71
http://www.jneuroinflammation.com/content/8/1/71
Page 2 of 8coated with MBP protein. Samples are added to the
appropriate microtiter plate wells and incubated. Horse-
radish Peroxidase (HRP) conjugated to anti-antibody is
added to each microplate well and incubated. Finally a
TMB (3,3’5,5’ tetramethyl-benzidine) substrate solution
is added to each well. Only those wells that contain
anti-MBP and enzyme-conjugated anti-antibody exhibit
a change in color. The enzyme-substrate reaction is ter-
minated by the addition of a sulphuric acid solution and
the color change is measured spectrophotometrically at
a wave length of 450 nm ± 2 nm. To increase accuracy,
all samples were analyzed twice in two independent
experiments to assess inter-assay variations and to
ensure reproducibility of the observed results (P > 0.05).
No significant cross-reactivity or interference was
observed.
Statistical analysis
The results were analyzed by commercially available
software package (Statview, Abacus concepts, inc., Berk-
ley, CA, USA). The data were non-parametric, thus they
were presented as median and interquartile range (IQR),
which are between the 25
th and 75
th percentiles. Mann-
Whitney test was used for comparison between these
data. Chi-square test was used for comparison between
qualitative variables of the studied groups. Spearman’s
rho correlation coefficient “r” was used to determine the
relationship between different variables. For all tests, a
probability (P) of less than 0.05 was considered signifi-
cant. Patients were considered to have elevated serum
serotonin or anti-MBP if their levels were above the
highest cut-off values (84.05 ng/ml and 221.55 ng/ml,
respectively) which were the 95
th percentiles of serum
serotonin and anti-MBP levels of healthy controls as the
distribution of the data was non-parametric.
3. Results
Serum serotonin levels in autistic children and their
relation to the degree of the severity of autism
Autistic children had significantly higher serum seroto-
nin levels [median (IQR) = 243.5 (119) ng/ml] than
healthy controls [median (IQR) = 41 (31) ng/ml], P <
0.001 (Figure 1). Increased serum serotonin levels were
found in 92% (46/50) of autistic patients.
Patients with severe autism had significantly higher
serum serotonin levels [median (IQR) = 268 (46) ng/ml]
than children with mild to moderate autism [median
(IQR) = 160 (84) ng/ml], P < 0.001 (Figure 2). Also, the
frequency of hyperserotonemia was significantly higher
in children with severe autism (100%) than patients with
mild to moderate autism (76.5%), P = 0.01.
Male and female autistic children had comparable
values of serum serotonin [median (IQR) = 251 (115)
ng/ml and 220 (92) ng/ml, respectively], P = 0.32. In
addition, serum serotonin levels had no significant cor-
relations with the age of the children with autism (P =
0.81).
Serum levels of anti-MBP auto-antibodies in autistic
children and its relation to the disease severity
Autistic children had significantly higher serum levels of
anti-MBP auto-antibodies than healthy controls, P <
Figure 1 Serum serotonin levels in autistic patients and
healthy children. Median value for each group is shown by a
horizontal bar.
Figure 2 Serum serotonin levels in relation to the degree of
the severity of autism. Median value for each group is shown by
a horizontal bar.
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serum anti-MBP auto-antibodies, increased serum levels
were found in 80% (40/50) of autistic patients.
There was a non-significant difference in serum levels
of anti-MBP auto-antibodies between children with
severe autism and patients with mild to moderate aut-
ism, P = 0.15 (table 1). In addition, there was a non-sig-
nificant difference in the frequency of seropositivity of
anti-MBP auto-antibodies between patients with severe
autism (81.8%) and children with mild to moderate aut-
ism (76.5%), P = 0.46.
Male and female autistic children had comparable
values of serum anti-MBP auto-antibodies [median
(IQR) = 476 (346) ng/ml and 365 (361) ng/ml, respec-
tively], P = 0.92. In addition, serum anti-MBP auto-anti-
bodies had no significant correlations with the age of
the children with autism (P = 0.75).
Relationship between hyperserotonemia and the
increased serum levels of anti-MBP auto-antibodies in
autistic children
There was a non-significant difference in serum levels of
anti-MBP auto-antibodies between autistic patients with
hyperserotonemia and patients with normal serum sero-
tonin levels, P = 0.74 (table 1). In addition, there was a
non-significant difference in the frequency of seroposi-
tivity of anti-MBP auto-antibodies between autistic
patients with hyperserotonemia (80.4%) and autistic
patients with normal serum serotonin levels (75%), P =
0.6 (table 2). Furthermore, there were no significant cor-
relations between serum levels of serotonin and anti-
MBP in autistic patients (P = 0.39).
4. Discussion
Autism without a discernible cause may be a genetic
disorder of serotonin metabolism [18]. Immune
abnormalities are also commonly observed in this disor-
der [1,25].
Elevated serotonin level in platelets, whole blood and
serum is the most consistent biochemical abnormality
found in autism [26]. In our series, autistic children had
significantly higher serum serotonin levels than healthy
controls (P < 0.001). In addition, increased serum sero-
tonin levels were found in 92% (46/50) of autistic
patients. Previous studies reported hyperserotonemia
and increased platelet serotonin in some autistic chil-
dren [27,28]. In one study hyperserotonemia was
reported in 55% of a group of 80 autistic children aged
between 3-12 years [29]. It was reported that 45% of the
fathers, 51% of the mothers and 87% of the normal sib-
lings of the autistic patients had elevated serotonin
levels [30]. Also, parents of autistic children, who them-
selves had elevated blood serotonin levels, recorded sig-
nificantly higher scores of depression and obsessive
compulsive disorders than parents with normal seroto-
nin levels [31]. Therefore, serotonin may represent a
marker for familial autism [32].
In the present work, all autistic patients were not
receiving any medications, including the selective sero-
tonin reuptake inhibitors. This may explain the
increased frequency of autistic patients with hypersero-
tonemia in this study. In addition, it was reported that
serum serotonin levels are affected by age as postpuber-
tal subjects had lower serum serotonin levels than pre-
pubertal subjects [33]. Thus, the variations of the age,
sex and race of the autistic patients between different
studies may be another explanations of the variations of
the frequency of hyperserotonemia between these
studies.
Platelet hyperserotonemia has been detected in 25-
60% of autistic children. The significant increase of the
level of serotonin mRNA in the platelets of some autis-
tic patients could suggest serotonin system dysregulation
in some patients with autism [34]. Research observing
the mechanism of hyperserotonemia indicated that it
might result from increase serotonin uptake by platelets
or decreased serotonin receptor binding sites on plate-
lets [31].
Among the potential environmental factors, hyperser-
otonemia during pregnancy and its effect on brain
development could be playing a role in autism. Hyper-
serotonemia during fetal development may result in a
Table 1 Serum levels of anti-MBP auto-antibodies in autistic patients and their relation to the degree of the severity
of autism and hyperserotonemia
Serum anti-MBP (pg/ml)
Median (IQR)
Z
(P)
Healthy children (n = 30) 92 (49) 6.85
Autistic children (n = 50) 465.5 (348) (< 0.001)
Patients with mild to moderate autism (n = 17) 334 (320) 1.45
Patients with severe autism (n = 33) 504 (328) (0.15)
Patients with normal serum serotonin (n = 4) 382 (453.5) 0.36
Patients with hyperserotonemia (n = 46) 476.5 (348) (0.74)
Anti-MBP, anti-myelin basic protein auto-antibodies. IQR, interquartile range.
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the amygdala as well as pro-social hormone oxytocin
regulation. Dysfunction of the amygdala and abnormal
oxytocin levels may underlie many clinical features of
autism [35]. Hyperserotonemia, is a common biomarker
in autism. The integrin b3 receptor subunit gene is a
quantitative trait locus for the whole blood serotonin
levels. Recent work shows that integrin b3 interacts with
the serotonin transporter (SERT) in both the platelets
and the midbrain in autism. Furthermore, multiple stu-
dies have now reported gene-gene interaction between
the integrin b3 and SERT genes in association with aut-
ism [36]. SERT has received considerable attention as a
potential risk locus for autism. One study reported a
possible role of alphaIIbbeta3/SERT associations as well
as alphaIIbbeta3 activation in control of SERT activity
in vivo that may have broad implications for hypersero-
tonemia, cardiovascular disorders, and autism [37].
In the present work, patients with severe autism had
significantly higher serum serotonin levels than patients
with mild to moderate autism (P < 0.001). In addition,
the frequency of hyperserotonemia was significantly
higher in children with severe autism (100%) than
patients with mild to moderate autism (76.5%), P = 0.01.
This may indicate that the extent of the elevation of
serum serotonin levels was closely linked to the degree
of the severity of autism. Previous research also reported
a close association between serum serotonin levels and
the severity of autism [29]. It is not easy to determine
whether hyperserotonemia is a mere consequence of
autism or has a pathogenic role in the disease.
Some studies reported that autistic patients with ele-
vated blood serotonin levels had elevated serotonin
transport into platelets [38]. However, the high seroto-
nin levels in the platelets do not necessarily mean that
this translates to high levels in the brain. In fact, there
are reasons to think otherwise. First: levels of 5-hydro-
xyindole acetic acid, the end product of serotonin meta-
bolism, have not been found to be elevated in
cerebrospinal fluid of autistic children [39]. Second: ser-
otonin reuptake inhibitors which increase brain seroto-
nin levels resulted in improvement of behavioral
disorders and language acquisition in 59% of autistic
children. Also, the decrease in brain serotonin following
acute tryptophan depletion resulted in worsening of
sterotyped movements in autistic children [18]. Third:
positron emission tomography neuroimaging using a
serotonin precursor, revealed diminished serotonin
synthesis in the left hemisphere in 5 out of 7 autistic
children [40]. Fourth: it was suggested that autistic chil-
dren may have an autoimmune disorder affecting brain
serotonin receptors since 7 out of 13 autistic children
had CSF antibodies against serotonin receptors [41]. So,
reduced brain serotonin content, which is important for
language production and sensory integration, may repre-
sent one mechanism underlying the pathophysiology of
autism [40].
Autoimmunity to CNS may have a pathogenic role in
autism [1]. This may be indicated by the presence of
brain-specific auto-antibodies in some autistic children
[2-8]. In our series, increased serum levels of anti-MBP
auto-antibodies were found in 80% (40/50) of autistic
patients. A previous study reported seropositivity of
anti-MBP protein auto-antibodies in 58% of autistic chil-
dren [2]. These antibodies have been observed to be
associated to viral serology as measles and herpes virus
6 [4], chlamydia pneumoniae and streptococcal M pro-
tein [42]. Other brain auto-antibodies such as anti-neu-
ron-axon filament protein, anti-glial fibrillary acidic
protein and anti-caudate nucleus were also reported to
be increased in patients with autism [3,5]. More
recently, seropositivity of anti-myelin-associated glyco-
protein, anti-neuronal and anti-ganglioside M1 antibo-
dies were reported in 62.5%, 54.5% and 74%,
respectively of autistic children [6-8]. Despite of the fact
that the origins of autoimmunity and the induction of
the production of brain auto-antibodies in autism are
unknown, the major histocompatibility complex genes
and their products (e.g., HLA-DRB1 and C4B null
alleles) might be involved [14,43].
MBP is a protein believed to be important in the pro-
cess of myelination of nerves in the central nervous sys-
tem. Interest in MBP has centered on its role in
demyelinating diseases, particularly multiple sclerosis
(MS). Several studies have shown a role for antibodies
against MBP in the pathogenesis of MS [44,45].
Table 2 Relationship between hyperserotonemia and the increased frequency of serum anti-MBP auto-antibodies in
autistic children
Patients with
autism
(n = 50)
Patients with normal serum serotonin
(n = 4)
Patients with elevated serum serotonin
(n = 46)
c
2
(P)
Patients with normal serum anti-MBP
(n = 10)
1 (25%) 9 (19.6%) 0.07
Patients with elevated serum anti-MBP
(n = 40)
3 (75%) 37 (80.4%) (0.6)
Anti-MBP, anti-myelin basic protein antibodies.
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antibodies in some patients with autism is not fully
understood. It is speculated that autoimmune reaction
to neurons might be trigged by cross-reacting antigens
in the environment resultingi nt h er e l e a s eo fn e u r o n a l
antigens. These neuronal antigens may result in induc-
tion of autoimmune reactions through the activation of
inflammatory cells in genetically susceptible individuals.
The environmental antigens may include food allergies
to certain peptides such as gliadin, cow’sm i l kp r o t e i n
and soy [46] infectious agents [1], heavy metals such as
mercury [47] and Heavea Brasiliensis proteins in natural
rubber latex [48]. Cross-reacting antigens in the envir-
onment may increase adhesion molecules on brain
endothelial cells. Pre-existing autoreactive T-cells trans-
migrate across the blood-brain barrier (BBB) and induce
activation of local antigen-presenting cells with produc-
tion of cytokines that may result in oligodendrocyte
damage and demyelination. These events may result in
the release of antigens from neurofilaments that enter
the circulation and induce the formation of plasma cells
which produce antibodies against neuron-specific anti-
gens. These antibodies may cross the BBB and combine
with brain tissue antigens forming immune complexes
that further damage the neurological tissue. Immu-
notherapy should be initiated in autistic children when a
clue of autoimmunity is evidenced by the presence of
auto-antibodies to CNS [42].
In our series, there was a non-significant difference in
serum levels of anti-MBP auto-antibodies between chil-
dren with severe autism and patients with mild to mod-
erate autism, P = 0.15. In addition, there was a non-
significant difference in the frequency of seropositivity
of anti-MBP auto-antibodies between patients with
severe autism (81.8%) and children with mild to moder-
ate autism (76.5%), P = 0.46. These findings may indi-
cate that the induction of the production of brain auto-
antibodies in some patients with autism may occur
regardless the degree of the disease severity.
Previous research had also found an increased fre-
quency of autoimmunity in families of autistic children
[9-15]. This may be an outstanding feature among autis-
tic patients that points to their autoimmune back-
ground; the target in their case being the developing
brain. This implies that in some families, immune dys-
function, perhaps induced by certain environmental trig-
gers, could express itself in the form of autism in one of
its offsprings.
To date, a definitive relationship between autism and
autoimmunity has not been fully established. On the
basis of the preliminary results reported in this study,
however, there seems to be a suggestive evidence in sup-
port of the induction of autoimmune reaction against
brain in some patients with autism. Additional
investigation designed to expand on these data is war-
ranted. Therapy in patients who are seropositive for
serum auto-antibodies is directed at reducing the anti-
body concentration, blocking the effector mechanisms
and depleting the monoclonal B cells. The recent avail-
ability of a monoclonal antibody suppressing B-cell
clones, which is not myelosuppressive and does not
cause secondary malignancies, allows for early targeted
intervention [49]. Preliminary results suggest that this
new line of therapy is well tolerated and is promising in
the treatment of some patients [50,51]. Thus, we suggest
that further studies with a larger subject population
should be conducted to investigate the possiblr role of
this therapy in autistic patients who have increased
serum levels of anti-MBP auto-antibodies.
Serotonin has been shown to modulate some immune
responses and hyperserotonemia may explain some of
the abnormal cellular immune responses seen in autism.
Serotonin has an important role in initiation of delayed-
type hypersensitivity responses [52], which are impor-
tant in autoimmunity, as serotonin initiates the activa-
tion of local endothelial cells to recruit effector T cells,
and activates serotonin receptors on these recruited
cells [53]. Some researchers found a correlation between
serum serotonin levels and the presence of certain
major histocompatibility complex (MHC) genes (the
extended haplotype B44-DR4 and the C4B null allele)
[54] which had previously reported to be associated with
autism and to play an important role in the develop-
ment of autoimmunity [14,43].
It is possible that a common factor could account for
both hyperserotonemia and immune abnormalities seen
in autism. Such common factor may be the serotonin
transporter (5-HTT) which transports serotonin into
platelets. 5-HTT is also found on immune cells where it
can influence immune function [55]. Some studies
found an association between autism and 5-HTT pro-
motor gene polymorphisms [32]. However, the meta-
analysis failed to find a significant overall association
between either of the 5-HTT polymorphisms examined
and autism [56]. In addition, hyperserotonemia may
promote autoimmunity through reduction of the pro-
duction of Th1-type cytokines resulting in an imbalance
of T-helper (Th)1/Th2 subsets toward Th2, which are
responsible for the production of antibodies [21]. This
imbalance was reported in some autistic patients [1].
I nt h i sw o r k ,w eh a v et r i e dt of i n dap o s s i b l er e l a t i o n
between the elevated serum levels of serotonin and anti-
MBP auto-antibodies. There was a non-significant dif-
ference in serum levels of anti-MBP auto-antibodies
between autistic patients with hyperserotonemia and
autistic patients with normal serum serotonin levels, P =
0.74. In addition, there was a non-significant difference
in the frequency of seropositivity of anti-MBP auto-
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mia (80.4%) and autistic children with normal serum
serotonin levels (75%), P = 0.6. Furthermore, there was
a non-significant correlation between serum serotonin
and anti-MBP levels in autistic patients (P = 0.39). We
could not trace data in the literature concerning the
relationship between hypersrotonemia and brain auto-
antibodies in autistic patients to compare our results.
We are the first to study such a relationship. This war-
rants further research to determine the possible link
between hyperserotonemia and the elevated serum levels
of brain auto-antibodies which are detected in a sub-
group of autistic patients.
The results of this study may indicate that hypersero-
tonemia is not one of the contributing factors to the
increased frequency of anti-MBP auto-antibodies in
some autistic children. However, this initial report can
not rule out the possible association between hypersero-
tonemia and immune abnormalities that had been
reported in autism, but rather raises additional ques-
tions. So, these data should be treated with caution until
further investigations are performed. Therefore, studies
should be conducted to investigate the possible associa-
tion between hyperserotonemia and immune abnormal-
ities in autism.
Conclusions
Hyperserotonemia may not be one of the contributing
factors to the increased frequency of serum anti-MBP
auto-antibodies in some autistic children. These data
should be treated with caution until further investiga-
tions are performed. However, inclusion of serum sero-
tonin levels as a correlate may be useful in other future
immune studies in autism to help unravel the long-
standing mystery of hyperserotonemia and its possible
role in the pathophysiology of this disorder. In addition,
the possible role of blood serotonin lowering drugs in
amelioration of immune abnormalities in hyperserotone-
mic autistic children should also be studied.
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